

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

ANNOUNCEMENT PROFIT WARNING

This announcement is made by Yestar Healthcare Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby informs the shareholders and potential investors of the Company that, based on the currently available unaudited management accounts of the Group for the six months ended 30 June 2026 (the “**Interim Period 2026**”) and the preliminary assessment by the Company’s management, the Group is expected to record an unaudited consolidated net loss of the Group of not less than RMB0.45 million for the Interim Period 2026 as compared to an unaudited consolidated net profit of the Group of approximately RMB11.1 million for the six months ended 30 June 2025 (the “**Interim Period 2025**”).

The expected turnaround from net profit to net loss of the Group for the Interim Period 2026 is primarily attributed to a decrease in revenue from our medical products segment due to the downward pricing pressure driven by the implementation of China’s national and provincial drug bulk schemes which encouraged distributors and service providers to purchase related medical products in bulk directly from the National Healthcare Security Administration with lower competitive cost.

The Group is still in the process of finalizing its unaudited consolidated results for the Interim Period 2026. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited management accounts of the Group for the Interim Period 2026 and the information currently available to the Board, which may be subject to further adjustments after further internal review by the Board. Details of the unaudited financial performance of the Group will be contained in the interim results announcement of the Group for the Interim Period 2026, which is expected to be published on 28 August 2026.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Wang Chunlai
Executive Director and Chief Executive Officer

17 August 2026

As at the date of this announcement, the executive Directors are Mr. Wang Chunlai, Mr. Qiao Jinrong and Ms. Liao Changxiang; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Koeswondo Michael David.